If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
=== October === 1 October – PPE Medpro is ordered to pay back £122m to the government after supplying non-compliant medical gowns during the COVID-19 pandemic. 2 October – Former Conservative MP Sarah Atherton joins Reform UK and says she wants to stand in the 2026 Senedd election. Reform UK-led Nottinghamshire County Council partially lift the ban they imposed on the Nottingham Post in response to a request to lift it in full from a law firm representing the publishers. Kemi Badenoch pledges to repeal the Climate Change Act 2008. 3 October – Dame Sarah Mullally is named as the first female Archbishop of Canterbury, replacing Justin Welby following his resignation. Zack Polanski makes his keynote speech as leader of the Green Party of England and Wales at their annual conference. Shabana Mahmood calls Pro-Palestinian protests "un-British" following the 2025 Manchester synagogue attack. Michelle Mone, Baroness Mone says she has no wishes to return to the House of Lords. 4 October – The 2025 Conservative Party Conference begins in Manchester. London Assembly member Keith Prince defects from the Conservative Party to Reform UK. 5 October – The Conservatives say they would task officials with deporting 750,000 migrants over five years if they form the next government. 7 October – The Guardian publishes video footage of Robert Jenrick, the Shadow Justice Secretary, describing the Handsworth area of Birmingham as "one of the worst-integrated places" in the UK during an after dinner speech recorded in March. 20 Conservative councillors defect to Reform UK.
Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo (deutetrabenazine) which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy (fremanezumab), used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. In 2023, Teva paid the largest fine to date for a domestic antitrust cartel in relation to a criminal investigation by the US Department of Justice into the company's price-fixing. One of its early shareholders, after the company was quoted on the Tel Aviv exchange, was the late British press tycoon Robert Maxwell.
=== Tag === The tag may be either a direct reporter, such as a fluorophore, or an affinity label such as biotin, or it may consist of a latent handle like an alkyne or azide for use with Huisgen 1,3-dipolar cycloaddition (also known as click chemistry). Reporter tags facilitate detection and isolation of labeled proteins. Common examples include fluorophores used for visualization via in-gel fluorescence and high-throughput gel-based screens, biotin for streptavidin-based enrichment followed by mass spectrometry, and isotopic labels for quantitative mass spectrometry. Alternatively, alkynes or azides can be incorporated as bio-orthogonal handles for post-labeling conjugation via click chemistry, enabling modular addition of fluorophores, affinity tags, or isotopic labels after proteome labeling. These "clickable" designs minimize steric hindrance at the active site and expand analytical flexibility, particularly for high-resolution liquid chromatography-mass spectrometry methods.
Sources: en.wikipedia.org
=== Spark Therapeutics === From 2014 to 2020, High was the co-founder, President, Chief Scientific Officer/Head of R&D and a Member of the Board of Directors of Spark Therapeutics, a fully integrated, commercial gene therapy company in Philadelphia. While at Spark Therapeutics, Dr. High led the team that obtained the first FDA approval of an AAV therapeutic (Voretigene neparvovec for the treatment of an inherited disorder causing blindness) in December 2017 and led the teams that obtained Breakthrough Therapy designation and FDA approval for Fidanacogene elaparvovec to treat Hemophilia B and Breakthrough Therapy designation for Dirloctogene samoparvovec to treat Hemophilia A. Spark Therapeutics was bought by Swiss pharma company Roche in December 2019 for $4.3 billion. In February 2020, High stepped down from her position at the company.
== Regulation == There are many mechanisms that exist to regulate the expression of system Xc-, although it is not the sole determinant of extracellular glutamate or intracellular glutathione. An example is amino acid deprivation, which triggers up regulation of the transporter. A key regulator is extracellular glutamate; when it becomes excessive, it goes from an excitatory transmitter to an excitotoxin. The inhibition of uptake of extracellular cystine into cells leads to decreased levels of intracellular glutathione which leads to ferroptosis. This regulation may be done through Excitatory Amino Acid Transporters (EAATs), which decrease extracellular glutamate and increase intracellular glutamate in astrocytes. When looking at its structure, xCT seems to be the main determinant for the system's activity. Glutamate and cystine can be transported in both directions, but, generally, more cystine is imported and more glutamate is exported. Extracellular glutamate acts as a competitive inhibitor for cystine uptake via system Xc-.
As of 8 July 2015, the High Court in Belgrade found that decree 392, issued by the Presidency of the Presidium of the National Assembly on 3 August 1947, which deprived King Peter II and other members of the House of Karađorđević of their citizenship, was null and void from the moment of its adoption, in the parts pertaining to Crown Prince Alexander, and that all of its legal consequences are thus null and void.
== Etymology == The term "Drosophila", meaning "dew-loving", is a modern scientific Latin adaptation from Greek words δρόσος, drósos, "dew", and φίλος, philos, "loving". The term "melanogaster", meaning "black belly", comes from Ancient Greek μέλας, mélas, "black", and γᾰστήρ, gastḗr, "belly".
Sources: en.wikipedia.org
The field of organic molecular cages emerged in the early 2000s, pioneered by the work of Cram, Lehn, and Pedersen, whose foundational research on host-guest chemistry and molecular recognition earned them the 1987 Nobel Prize. The area, which relies on molecular self-assembly, is inspired by biological precedents are ferritin, capsid, and the tobacco mosaic virus, which are formed by the self-assembly of protein subunits into a polyhedral symmetry. Large organic cages were reported by Tozawa and Cooper in 2009, introducing permanently porous organic cages with intrinsic cavities. The ability to control cavity size and chemical environment at the molecular level distinguishes these materials from traditional porous systems.
=== Legal status === Oveporexton was approved for medical use in China in July 2026, and in the United States in August 2026. The FDA granted the application for oveporexton breakthrough therapy and priority review designations. The approval of Orzeyful for the treatment of narcolepsy type 1 was granted to Takeda Pharmaceuticals America. Oveporexton is recommended for scheduling under the Controlled Substances Act and will be lawful to market in the US following the scheduling decision issued by the Drug Enforcement Administration.
Somalia was likely one of the first lands to be settled by early humans due to its location. Hunter-gatherers who would later migrate out of Africa likely settled here before their migrations. During the Stone Age, the Doian and Hargeisan cultures flourished here. The oldest evidence of burial customs in the Horn of Africa comes from cemeteries in Somalia dating back to the 4th millennium BC. The stone implements from the Jalelo site in the north were also characterised in 1909 as important artefacts demonstrating the archaeological universality during the Paleolithic between the East and the West. According to linguists, the first Afroasiatic-speaking populations arrived in the region during the ensuing Neolithic period from the family's proposed urheimat ("original homeland") in the Nile Valley, or the Near East. The Laas Geel complex on the outskirts of Hargeisa in northwestern Somalia dates back approximately 5,000 years, and has rock art depicting both wild animals and decorated cows. Other cave paintings are found in the northern Dhambalin region, which feature one of the earliest known depictions of a hunter on horseback. The rock art is dated to 1,000 to 3,000 BC. Additionally, between the towns of Las Khorey and El Ayo in northern Somalia lies Karinhegane, the site of numerous cave paintings, which collectively have been estimated to be around 2,500 years old. The camel is believed to have been domesticated in the Horn region between the 2nd and 3rd millennium BC. From there, it spread to Egypt and the Maghreb.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.